// App-Quantinova.ai

316 : EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A

Researchers

Presenter

  • Aurelien Marabelle

Principal Investigators

  • Christiane Jungels

  • Johann De Bono

  • Norbert Vey

  • Martin Wermke

  • Elena Garralda

  • Aude de Gassart

  • Patrick Brune

  • Emmanuel Valentin

  • Marina Ich

  • Daniel Olive

  • Paul Frohna

Medical Centers

  • Gustave Roussy, Villejuif, France

  • Institute Jules Bordet, Brussels, Belgium

  • The Institute of Cancer Research, London, UK

  • Institut Paoli-Calmettes, Marseille, France

  • Medical Faculty Carl Gustav Carus, Dresden, Germany,

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • ImCheck Therapeutics,Marseille,Frankrijk

  • ILife Consulting, Paris, France

  • Centre de recherche en Cancérologie, Marseille, France

Locations

  • France

  • Belgium

  • United Kingdom

  • Germany

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Interleukin 13

  • Interleukin-2

  • Interleukin 4

  • Interleukin-8

  • Interleukin 6

  • Interferon-gamma

  • Interleukin 1 beta

Drug/Treatment

  • Pembrolizumab

  • Interferon Gamma

  • IL-4

Outcome

  • N/A

Study Design

  • Open Label

  • First-In-Human

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved